Abstract 108P
Background
About 70% of patients with colorectal cancer develop liver metastases (LM). Although colorectal cancer patients with resectable LM have a good prognosis, there is little data at the difference in the locations of LM. We investigated how the location of LM affects prognosis of colorectal cancer patients.
Methods
The medical records of 196 colorectal cancer patients with liver metastasis from January 2008 to December 2018 were analyzed retrospectively. We defined liver metastasis within a 3-cm-radius sphere centered on the bifurcation of portal vein by computed tomography as central LM (group C), and other LM outside the 3-cm-radius sphere as peripheral LM (group P). We investigated the relation between location of LM and prognosis by using the Kaplan-Meier method and log-rank test, and the relation between location of LM and resection by using the chi-square test.
Results
Patient characteristics were as follows: median age 68.4 (range 30-87), female/male 115/81, colon/rectal cancer 117/79, advanced/recurrent 150/46, respectively. The characteristics of liver metastasis were as follows: mean maximum tumor size 38 mm (3 - 200), tumor number single/multi 58/138, group C/P 84/112, respectively. Median overall survival (OS) was 31 months [95% confidence interval (CI), 25.5 to 36.5 months] from the date of first diagnosis of LM. We divided 196 patients into two groups ofgroup C (n = 84) and group P (n = 112) by location of LM. Resection rate of LM was 11.9% (group C) and 50.9% (group P). Median OS in group C and group P was 18 months (95% CI, 12.3 to 23.7 months) and 38 months (95% CI, 35.2 to 40.8 months), respectively (p < 0.001). Resection of LM was performed significantly more often in group P than in group C (p < 0.001). Furthermore, the patients with resectable LM had a good prognosis not only in group P (mean OS 135 months, 95% CI, 109.4 to 160.7 months) but also in group C (mean OS 82 months, 95% CI, 67.5 to 96.0 months).
Conclusions
It is suggested that the colorectal cancer patients with peripheral LM might have a better prognosis than the patients with central LM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract